FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition with an activity activating lanthionine C-like 2 protein (LANCL2), containing an effective amount of a compound by the formula 
or a pharmaceutically acceptable salt thereof, wherein Q constitutes a piperazine-1,4-diyl; each of A1 and A1' independently constitutes N or CR6; each of A2 and A2' constitutes CR7; A3 constitutes NR8; A3' constitutes NR8 or O; each of A4 and A4' constitutes N; each of A5 and A5' constitutes CR10; each of A6 and A6' constitutes CR11; and each of R1, R1', R2, R2', R3, R3', R4, R4', R6, R7, R8, R10 and R11 constitutes hydrogen; and a carrier.
EFFECT: new pharmaceutical composition is produced, applicable in medicine for treating a number of conditions, including an infectious disease, an autoimmune disease, diabetes, and a chronic inflammatory disease.
41 cl, 40 dwg, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINES BASED ON LANTIONINE SYNTHETASE OF C-LIKE PROTEIN 2 | 2015 |
|
RU2741576C2 |
| DRUG PREPARATIONS BASED ON LANTHIONINE SYNTHETASE OF C-LIKE PROTEIN | 2015 |
|
RU2688677C2 |
| QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | 2015 |
|
RU2760686C2 |
| NEW INHIBITORS OF ALPHA AND BETA MEPRIN | 2017 |
|
RU2746850C2 |
| INDENE DERIVATIVES APPLICABLE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2012 |
|
RU2601307C2 |
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
| NOVEL PROSTAGLANDIN I DERIVATIVE | 2009 |
|
RU2509768C2 |
| USE OF MICROBIAL COMMUNITIES FOR THE TREATMENT OF HUMANS AND ANIMALS | 2017 |
|
RU2758387C2 |
| PPAR MODULATORS | 2007 |
|
RU2449999C2 |
| USE OF MICROBIAL COMMUNITIES FOR TREATING HUMANS AND ANIMALS | 2017 |
|
RU2823233C2 |
